Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Nuvectis Pharma, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 37 | 33 | −4 |
| Shares | 1.25M | 1.28M | +24.4K (+1.9%) |
| Value | $20.0M | $16.5M | −$3.57M (−17.8%) |
New holders (1)
Institutions that held Nuvectis Pharma, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Moran Wealth Management, LLC | 16,697 | $215.2K | 0.01% |
Sold out (5)
Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Citadel Advisors LLC | 28,028 | $447.6K |
| Edmond de Rothschild Holding S.A. | 22,820 | $364.4K |
| Bank of Montreal | 11,012 | $200.0K |
| MetLife Investment Management | 3,970 | $63.4K |
| Metropolitan Life Insurance Co | 411 | $6.56K |